EsoBiotec to present pre-clinical data on ENaBL-T CAR-T cell therapy platform.

EsoBiotec, a clinical-stage biotechnology company, will present pre-clinical proof of concept data for its Engineered NanoBody Lentiviral (ENaBL) vector, ENaBL-T, for in vivo CAR-T cell therapies. The data will be presented as posters at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. ENaBL-T is a lentiviral vector for in vivo engineering of BCMA CAR T cells, which has supported the first in vivo BCMA CAR-T cell therapy clinical trial for patients with relapse or refractory multiple myeloma.

Adicet Bio, Inc. (ACET) and Allarity Therapeutics, Inc. (ALLR) have both announced significant advancements in their respective pipeline of cancer therapies, with oral presentations scheduled at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, Louisiana. These announcements highlight the companies' ongoing efforts to revolutionize cancer treatment through innovative therapeutic approaches.

Adicet Bio, a leader in developing allogeneic gamma delta T cell therapies, will present preclinical data on ADI-270 at ASGCT 2025. The presentation, titled "Engineered Immune Effector Cells for Solid Tumors," will be given by Melinda Au on May 17, 2025, from 11:45 a.m. to 12:00 p.m. Central Time. ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor (CAR) T cell therapy, showcases robust CAR-directed and independent anti-tumor activity against both hematologic and solid tumor models. This innovative therapy aims to provide a significant advantage over conventional CAR T cells [1].

Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company, will present a poster containing data on a new Drug Response Predictor (DRP) for the monoclonal antibody drug daratumumab at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. The poster, titled "An mRNA-based predictor of response to daratumumab in multiple myeloma," will be presented during a session on April 27, 2025, from 2:00 PM to 5:00 PM CT. This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab, using gene expression patterns correlated with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC). The DRP was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC), based on published in vitro data from multiple myeloma and B-cell lymphoma cell lines [2].

These presentations underscore the companies' commitment to advancing precision medicine and personalized cancer treatments. Adicet Bio continues to advance its pipeline of 'off-the-shelf' T cell therapies designed to provide durable activity in patients with cancer and autoimmune diseases. Allarity Therapeutics, on the other hand, is expanding its DRP platform to include antibody-based therapies, demonstrating the versatility and flexibility of its technology.

References:
[1] https://www.gurufocus.com/news/2809361/adicet-bio-announces-oral-presentation-highlighting-preclinical-adi270-data-at-the-american-society-of-gene-and-cell-therapy-asgct-28th-annual-meeting-acet-stock-news
[2] https://www.biospace.com/press-releases/allarity-therapeutics-presents-novel-drug-response-predictor-drp-for-daratumumab-in-multiple-myeloma-at-aacr-2025